---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011134"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:19:06.598742+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar licenses three novel peptides from Anji for up to $453M total

## Summary
- Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.
- First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.
- Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.
- Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.
- Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry.

## SEC filing metadata
- accession: 0001558370-25-011134
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/0001558370-25-011134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/amph-20250808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011134
- JSON: https://secwatch.observer/filing/0001558370-25-011134.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.